Article
Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)₇TAA and UGT1A4 L48V polymorphisms.
Pharmacogenetics and genomics - 1 Aug 2012
Erickson-Ridout Kathryn K, Sun Dongxiao, Lazarus Philip
Abstract excerpt
INTRODUCTION: Clozapine (CLZ) is an FDA approved second-generation antipsychotic for refractory schizophrenia, and glucuronidation is an important pathway in its metabolism. The aim of this study was to fully characterize the CLZ glucuronidation pathway and examine whether polymorphisms in active glucuronidating enzymes could contribute to variability in CLZ metabolism. METHODS: Cell lines overexpressing...
Topics
- Alleles
- Antipsychotic Agents
- Cell Line
- Clozapine
- Genotype
- Glucuronides
- Glucuronosyltransferase
- Humans
- Kinetics
- Microsomes, Liver
- Polymorphism, Genetic
- Schizophrenia